These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23250623)

  • 1. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
    Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
    Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.
    Suttorp M; Claviez A; Bader P; Peters C; Gadner H; Ebell W; Dilloo D; Kremens B; Kabisch H; Führer M; Zintl F; Göbel U; Klingebiel T
    Klin Padiatr; 2009; 221(6):351-7. PubMed ID: 19890786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.
    Topcuoglu P; Arat M; Ozcan M; Arslan O; Ilhan O; Beksac M; Gurman G
    Ann Hematol; 2012 Apr; 91(4):577-86. PubMed ID: 21971669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
    Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
    Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Todorić-Zivanović B; Ostojić G; Tatomirović Z; Marjanović S; Malesević M
    Vojnosanit Pregl; 2012 Jan; 69(1):37-42. PubMed ID: 22397295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.
    Zuckerman T; Katz T; Haddad N; Fineman R; Dann EJ; Avivi I; Ofran Y; Gavish I; Faibish T; Sahar D; Hertz E; Sabo E; Reisner Y; Rowe JM
    Am J Hematol; 2012 Sep; 87(9):875-9. PubMed ID: 22847303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
    De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
    Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
    Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
    Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Byeun JY; Park JE; Jeon HR; Oh YJ; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Lee JW; Min WS; Park CW; Kim DW
    Hematology; 2014 Mar; 19(2):63-72. PubMed ID: 23684143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
    Warlick E; Ahn KW; Pedersen TL; Artz A; de Lima M; Pulsipher M; Akpek G; Aljurf M; Cahn JY; Cairo M; Chen YB; Cooper B; Deol A; Giralt S; Gupta V; Khoury HJ; Kohrt H; Lazarus HM; Lewis I; Olsson R; Pidala J; Savani BN; Seftel M; Socié G; Tallman M; Ustun C; Vij R; Vindeløv L; Weisdorf D
    Blood; 2012 Apr; 119(17):4083-90. PubMed ID: 22408257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
    Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
    Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.